[
  {
    "ts": null,
    "headline": "Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025?",
    "summary": "Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind it? This article will walk you through what the numbers are really saying about its value. The stock is up 4.1% over the last month and 11.4% year to date, even though the 1 year return is slightly negative at -2.5%. This hints at a mix of renewed optimism and lingering caution after a strong 3 year gain of 48.3%. Recent attention has focused on Vertex’s expanding...",
    "url": "https://finnhub.io/api/news?id=53026784c6fe4955a0aba2151e4a1bbb11029815d7a91cbb2e310f3b8c7659a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765645921,
      "headline": "Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025?",
      "id": 137792644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind it? This article will walk you through what the numbers are really saying about its value. The stock is up 4.1% over the last month and 11.4% year to date, even though the 1 year return is slightly negative at -2.5%. This hints at a mix of renewed optimism and lingering caution after a strong 3 year gain of 48.3%. Recent attention has focused on Vertex’s expanding...",
      "url": "https://finnhub.io/api/news?id=53026784c6fe4955a0aba2151e4a1bbb11029815d7a91cbb2e310f3b8c7659a1"
    }
  },
  {
    "ts": null,
    "headline": "How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review",
    "summary": "Vertex Pharmaceuticals recently reported clinical data showing that CASGEVY helped all evaluable children aged 5–11 with severe sickle cell disease or transfusion‑dependent beta thalassemia meet key 12‑month endpoints, and it also received a U.S. FDA Commissioner’s National Priority Voucher to speed review for this younger age group. This combination of strong pediatric results and accelerated FDA review could meaningfully expand CASGEVY’s eligible patient pool and reinforce Vertex’s...",
    "url": "https://finnhub.io/api/news?id=154cc12f935fdeb0b35329e75e16a55873192a476986bcb0b484b118351ee4b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765638933,
      "headline": "How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review",
      "id": 137792645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals recently reported clinical data showing that CASGEVY helped all evaluable children aged 5–11 with severe sickle cell disease or transfusion‑dependent beta thalassemia meet key 12‑month endpoints, and it also received a U.S. FDA Commissioner’s National Priority Voucher to speed review for this younger age group. This combination of strong pediatric results and accelerated FDA review could meaningfully expand CASGEVY’s eligible patient pool and reinforce Vertex’s...",
      "url": "https://finnhub.io/api/news?id=154cc12f935fdeb0b35329e75e16a55873192a476986bcb0b484b118351ee4b3"
    }
  }
]